A 35-year-old woman with established schizophrenia on risperidone develops significant weight gain (8 kg over 3 months) and elevated fasting glucose (120 mg/dL). She remains symptomatically stable. Which antipsychotic is the best alternative to minimize metabolic side effects while maintaining efficacy?

Explanation

## Antipsychotic Switch for Metabolic Complications **Key Point:** Aripiprazole is the atypical antipsychotic with the most favorable metabolic profile (minimal weight gain, no glucose elevation) and is the preferred switch option when metabolic side effects emerge on other atypicals. ### Metabolic Profile Comparison | Antipsychotic | Weight Gain | Glucose/Lipids | Metabolic Syndrome Risk | Best For | |---|---|---|---|---| | **Aripiprazole** | **Minimal–none** | **Neutral** | **Very low** | **Metabolic concerns** | | Risperidone | Mild–moderate | Mild elevation | Moderate | Standard use | | Olanzapine | **Severe** | **Significant** | **Very high** | Avoid if metabolic risk | | Quetiapine | Moderate–severe | Moderate elevation | Moderate–high | Avoid if metabolic risk | | Paliperidone | Mild–moderate | Mild elevation | Moderate | Similar to risperidone | **High-Yield:** Aripiprazole's unique mechanism (partial dopamine agonist, not full antagonist) explains its metabolic neutrality — it does not increase prolactin or cause the insulin resistance seen with full D~2~ antagonists. ### Clinical Rationale for Aripiprazole Switch 1. **Metabolic safety:** No weight gain, no glucose dysregulation, no lipid elevation. 2. **Maintained efficacy:** Comparable antipsychotic potency to risperidone; patient is symptomatically stable, so switch is low-risk. 3. **Dose equivalence:** Risperidone 5–6 mg ≈ Aripiprazole 15 mg (allows direct cross-titration). 4. **Additional benefits:** Lower prolactin elevation (may improve sexual function if impaired). **Clinical Pearl:** Aripiprazole is also the preferred agent in patients with: - Baseline obesity or diabetes - Metabolic syndrome - Hyperprolactinemia-related sexual dysfunction - Cardiovascular risk factors **Mnemonic — Metabolically Favorable Atypicals (AAAA):** Aripiprazole, Amisulpride (if available). These are the only atypicals with truly neutral metabolic profiles. ### Why Not the Other Options? **Olanzapine:** Causes the most severe weight gain (average 5–7 kg) and significant glucose dysregulation. Switching to olanzapine would worsen the very problem you are trying to solve. **Quetiapine:** Moderate–severe weight gain and glucose elevation. Better than olanzapine but inferior to aripiprazole for metabolic concerns. **Paliperidone:** Similar metabolic profile to risperidone (its parent compound). Would not solve the current weight gain and glucose issues. [cite:KD Tripathi 8e Ch 12; Harrison 21e Ch 397]